Burkitt lymphoma

Rapidly enlarging lymph nodes or an abdominal mass, pain, vomiting, systemic symptoms and marrow-related low counts may be presenting features. Breathing difficulty, reduced urine, confusion, severe abdominal symptoms or bleeding needs immediate clinical assessment.

This is usually not a disease to place on an ordinary watch-and-wait pathway. The team coordinates biopsy, organ assessment and supportive care in parallel. A second opinion can be useful, but should not delay stabilization of an emergency.

Diagnosis combines characteristic morphology, a mature B-cell/germinal-center phenotype, very high proliferation and MYC-related genetics. MYC rearrangement alone does not define Burkitt lymphoma; DLBCL and other high-grade B-cell entities can also carry it.

Current classification recognizes the biological importance of EBV status. A Burkitt-like appearance with an 11q aberration can represent a different entity. Expert pathology review should clarify an ambiguous report without unnecessarily delaying care.

Imaging, LDH, kidney function, electrolytes, blood and marrow findings define disease extent and immediate risks. HIV testing and other infection screening help plan treatment and support. Adults and children use risk systems tailored to their protocols.

Lumbar puncture with appropriate cerebrospinal-fluid testing is considered when clinically safe; flow cytometry can add sensitivity to cytology. Neurological symptoms may require brain or spine imaging. CNS involvement changes therapy, rather than merely adding another stage label.

Rapid cell breakdown can raise uric acid, potassium and phosphate, lower calcium and injure the kidneys or heart. Prevention may include supervised hydration, uric-acid-lowering treatment and frequent laboratory monitoring; high-risk patients often need inpatient care.

Rasburicase requires attention to G6PD deficiency and other contraindications. Fluid plans must account for renal or cardiac problems. Infection prevention, transfusion support, mucositis care and nutrition are essential parts of delivering treatment on schedule.

Disease-specific approaches include rituximab-containing CODOX-M/IVAC, hyper-CVAD-based programs and risk-adapted DA-EPOCH-R in appropriate settings. These differ in intensity, inpatient time and CNS coverage. Standard R-CHOP should not simply be substituted because it is familiar for DLBCL.

The randomized HOVON/SAKK comparison was stopped early because of slow recruitment and studied patients without CNS involvement. DA-EPOCH-R had less treatment-related toxicity, but the limited trial does not prove that the regimens are interchangeable for every high-risk or CNS-positive patient.

The multicenter DA-EPOCH-R study supported risk-adapted treatment across adult age groups and HIV status, while identifying CNS-positive disease as an unmet need. Dose adjustment, number of cycles and intrathecal treatment are protocol decisions; they should not be reconstructed from a drug list.

Children and adolescents are usually treated through pediatric mature B-cell protocols with risk-adapted intensity. Randomized evidence supports adding rituximab to chemotherapy for high-risk mature B-cell lymphoma; it does not mean every low-risk child needs the same exposure.

Immune recovery and infection surveillance matter after rituximab. HIV-positive adults can receive curative treatment, with antiretroviral and drug-interaction management. Frail adults or patients with major organ dysfunction need specialist adaptation rather than a simple age-based exclusion.

Response is assessed according to the protocol with imaging and reassessment of initially involved compartments when relevant. A residual mass or PET focus may require confirmation before declaring resistance. Completing the planned regimen remains important even after rapid visible shrinkage.

Relapsed/refractory disease is difficult to treat and needs urgent expert review. Salvage combinations, trial enrollment and selected transplantation are considered according to response, organ reserve and previous therapy. The goal and chance of reaching a definitive next step should be discussed early.

Burkitt lymphoma should not be treated as though it automatically shares every DLBCL CAR-T indication. A multicenter adult retrospective cohort found responses but frequent early progression, showing why an initial response rate is not enough to claim durable benefit.

Pediatric sequential antigen-targeted studies and newer dual-target approaches are investigational. A recent CD19/CD22 phase I report was mainly B-ALL and included only two Burkitt patients at the recommended dose; its aggregate outcomes cannot be presented as a Burkitt cure rate.

Review the exact trial, disease-specific enrollment, manufacturing delay, bridging plan and whether transplantation is intended after response. Rapid disease makes these practical details particularly consequential.

Bring pathology and MYC/FISH results, baseline and current imaging, marrow/CSF reports, kidney and electrolyte trends, and the exact treatment schedule including CNS doses. State whether deterioration or a treatment delay is occurring now.

After treatment, follow-up addresses recurrence symptoms, immune recovery, cardiac exposure, fertility and age-appropriate growth and learning. A rapid initial response is encouraging, but recovery and surveillance still need a written plan.